IPSEN (OTCMKTS:IPSEY - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $29.38 and traded as high as $30.72. IPSEN shares last traded at $30.72, with a volume of 2,563 shares changing hands.
Wall Street Analyst Weigh In
Separately, Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of IPSEN in a report on Wednesday, April 2nd.
Get Our Latest Stock Report on IPSEY
IPSEN Price Performance
The company has a 50 day moving average of $29.62 and a 200 day moving average of $29.44.
IPSEN Increases Dividend
The company also recently disclosed a dividend, which was paid on Wednesday, June 25th. Investors of record on Tuesday, June 10th were issued a $0.2896 dividend. This is a positive change from IPSEN's previous dividend of $0.23. This represents a yield of 0.97%. The ex-dividend date was Monday, June 9th.
IPSEN Company Profile
(
Get Free Report)
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
See Also
Before you consider IPSEN, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IPSEN wasn't on the list.
While IPSEN currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
